Top Markets
Coin of the day
ABVC BioPharma, Inc. ABVC BioPharma, Inc.

ABVC BioPharma, Inc.

ABVC
주식 순위 #28871
ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on... ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on creating novel drugs and medical devices to address critical, underserved healthcare requirements across the United States. The company's pipeline includes several key candidates: ABV-1501, currently undergoing Phase I/II clinical trials, is being developed as a combination treatment for triple-negative breast cancer. ABV-1504 has successfully completed Phase II clinical trials for major depressive disorders. ABV-1505 is progressing through Phase II clinical studies for attention deficit hyperactivity disorder (ADHD). ABV-1703 has concluded its Phase I clinical trials for the treatment of pancreatic cancer. ABV-1702 has also finished Phase I clinical investigations for myelodysplastic syndromes. ABV-1601 is in Phase I/II clinical trials, aimed at alleviating depression in individuals with cancer. ABV-1701 Vitargus is in development to treat conditions such as retinal detachment or vitreous hemorrhage. ABVC BioPharma maintains strategic alliances, including a co-development arrangement with Rgene Corporation, alongside collaborative agreements with BioHopeKing Corporation and BioFirst Corporation. The company's headquarters are located in Fremont, California, and it operates as a subsidiary of YuanGene Corporation.
주가
$0.9142
시가총액
$23.77M
변동 (1일)
5.55%
변동 (1년)
-67.92%
국가
US
거래 ABVC BioPharma, Inc. (ABVC)

카테고리

ABVC BioPharma, Inc. (ABVC)의 P/S 비율
2026 기준 P/S 비율 TTM: 0
ABVC BioPharma, Inc.의 최신 재무 보고서와 주가에 따르면 현재 P/S 비율(TTM)은 0입니다. 2026년 말 기준 P/S 비율은 0였습니다.
ABVC BioPharma, Inc.의 P/S 비율 기록 (2026 ~ 2026)
매년 말 P/S 비율
연도 P/S 비율 변화
제공된 날짜에 대한 데이터가 충분하지 않습니다.
유사 기업 또는 경쟁사의 P/S 비율
회사 P/S 비율 P/S 비율 차이 국가
10.17 -
US
10.13 -
NL
11.28 -
US
2.95 -
AU
- -
CH